Diligence memo · auto-generated · as of July 2, 2026
Cxl Ophthalmics, Inc.
Cxl Ophthalmics, Inc. looks over-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Cxl Ophthalmics, Inc. operates in Pharmaceuticals, based in SHERBORN.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Cxl Ophthalmics, Inc. has raised $26M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $26M on 2022-09-28.
Most recent recorded round closed around 2022-09-28.
Valuation (modeled)modeled
Provath models Cxl Ophthalmics, Inc. at approximately $370M (range $55M–$928M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 2.85× the median modeled value of Series B Pharmaceuticals companies in 2022–2024 (51 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Last raise 3.8 yr ago; this sector typically re-raises about every 13 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 71% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 77% of those peers.
Closest niche peers: MedAvail Holdings, Inc., Revalesio Corp, Kinaset Therapeutics, Inc., Venatorx Pharmaceuticals, Inc., Delex Healthcare Group, Inc..
Peoplefiled
6 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.